Benzinga··Gav BlaxbergEdgewise Therapeutics' $3.1B Bet on Two Blockbuster Drug Candidates
Edgewise Therapeutics pursues two major drug candidates addressing unmet cardiac and muscular disease needs, with pivotal data expected through 2026.
BMYCELGrALNYEWTXFDA approvalbiotech